68,001 Arrowhead Pharmaceuticals, Inc. $ARWR Shares Bought by CenterBook Partners LP

CenterBook Partners LP increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 344.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 87,729 shares of the biotechnology company’s stock after acquiring an additional 68,001 shares during the quarter. CenterBook Partners LP owned approximately 0.06% of Arrowhead Pharmaceuticals worth $5,742,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Heritage Family Offices LLP bought a new stake in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Arrowhead Pharmaceuticals in the 3rd quarter worth about $472,000. Profund Advisors LLC grew its position in Arrowhead Pharmaceuticals by 32.0% during the third quarter. Profund Advisors LLC now owns 29,282 shares of the biotechnology company’s stock valued at $1,917,000 after buying an additional 7,092 shares during the period. Vise Technologies Inc. grew its position in Arrowhead Pharmaceuticals by 52.6% during the third quarter. Vise Technologies Inc. now owns 7,102 shares of the biotechnology company’s stock valued at $465,000 after buying an additional 2,448 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Arrowhead Pharmaceuticals by 15.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 25,773 shares of the biotechnology company’s stock valued at $1,707,000 after buying an additional 3,356 shares during the period. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Insider Buying and Selling

In related news, Director Adeoye Olukotun sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. This represents a 5.95% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Perry sold 11,600 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock traded up $0.70 on Friday, hitting $58.16. 1,363,195 shares of the stock were exchanged, compared to its average volume of 1,708,830. The firm’s 50 day moving average is $66.91 and its two-hundred day moving average is $71.48. Arrowhead Pharmaceuticals, Inc. has a one year low of $37.06 and a one year high of $95.49. The firm has a market capitalization of $8.19 billion, a PE ratio of -25.85 and a beta of 1.34. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company’s revenue was up 171.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.26) earnings per share. Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Monday, August 17th. Citigroup began coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 8th. They set a “buy” rating and a $108.00 target price for the company. Morgan Stanley raised their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Piper Sandler restated an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $115.00 price target on shares of Arrowhead Pharmaceuticals in a report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.07.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.